<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The potential of EHT 6706, a novel tubulin-binding agent, was investigated in combination with ionizing radiation (IR) and with conventional cytotoxic chemotherapy agents </plain></SENT>
<SENT sid="1" pm="."><plain>Cell proliferation, cell cycle, <z:mpath ids='MPATH_3'>apoptosis</z:mpath> and clonogenic assays were performed in five human <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cell lines: H460 (non small cell <z:mp ids='MP_0008714'>lung carcinoma</z:mp>, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NSCLC</z:e>), HCT116 and HCT116 p53-/- (<z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>), <z:chebi fb="14" ids="32506">MDA</z:chebi>-MB-231 (<z:hpo ids='HP_0003002'>breast cancer</z:hpo>), and MiaPaca2 cells (<z:hpo ids='HP_0002894'>pancreatic cancer</z:hpo>) </plain></SENT>
<SENT sid="2" pm="."><plain>The drug inhibited cell proliferation in <z:hpo ids='HP_0000001'>all</z:hpo> cell lines </plain></SENT>
<SENT sid="3" pm="."><plain>This effect was associated with G2/M arrest and activation of <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in a dose-dependent manner </plain></SENT>
<SENT sid="4" pm="."><plain>The drug was then tested in combination with chemotherapy and IR in vitro </plain></SENT>
<SENT sid="5" pm="."><plain>Effects on proliferation and clonogenic survival were analyzed </plain></SENT>
<SENT sid="6" pm="."><plain>EHT 6706 treatment inhibited clonogenic survival synergistically with IR in H460 and MiaPaca2 cell lines </plain></SENT>
<SENT sid="7" pm="."><plain>In the remaining cell lines, the effects of EHT 6706 and IR were additive </plain></SENT>
<SENT sid="8" pm="."><plain>For H460 and MiaPaca2 cell lines, the highest effect was seen when cells were exposed for 20 h to EHT 6706 before being irradiated </plain></SENT>
<SENT sid="9" pm="."><plain>EHT 6706 also exerted additive inhibition of proliferation when given in combination with conventional chemotherapy agents, such as <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi>, <z:chebi fb="2" ids="27899">cisplatin</z:chebi> and <z:chebi fb="0" ids="175901">gemcitabine</z:chebi> in H460 and MiaPaca2 <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cell lines </plain></SENT>
<SENT sid="10" pm="."><plain>These data show that EHT 6706 could act synergistically with IR and additively with chemotherapy in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cell lines in vitro </plain></SENT>
<SENT sid="11" pm="."><plain>This provides a good rationale to further assess EHT 6706 in combination protocols and confirm these effects in vivo </plain></SENT>
</text></document>